Determined to take the company’s next-generation engineered cell therapies to the next level, BlueRock Therapeutics is teaming up with Senti Biosciences with futuristic medicines in mind.  

Cryoport Inc. appointed creative communications agency Mind+Matter, an Ashfield Health company and part of UDG Healthcare, as the company’s strategic marketing partner to support the rebrand of the entire business alongside a strategic communications plan.

MiMedx Group Inc., an industry leader in utilizing birth tissue as a platform for regenerative medicine, announced the appointment of Phyllis Gardner, M.D. to the Board of Directors.

Regenerative medicine company AVITA Therapeutics Inc. announced the appointment of Kathy McGee as Chief Operating Officer, effective December 1, 2020.

Vineti and EVERSANA announced a partnership to improve access, affordability and patient support challenges in regenerative medicine.

With $76 million in financing, San Diego-based Autobahn Therapeutics is hitting the ground with a goal of developing regenerative medicines aimed at treating disorders of the central nervous system (CNS).

Cryoport Inc. and EVERSANA announced a strategic alliance to further create a fully integrated regenerative medicine supply chain solution.

Smith & Nephew Plc will buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing.

South Korea’s Biostar Stem Cell Research Institute – jointly operated by Nature Cell and Rbio – announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12.

Athersys Inc. and Mesoblast Ltd. are beginning final-stage trials in hundreds of patients that they – along with loyal investors – say could change the course of devastating stroke and heart failure.